Neurocrine Advances Obesity Pipeline with Phase 1 Trial of Triple Agonist
Event summary
- Neurocrine Biosciences initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist targeting obesity.
- The trial will evaluate safety and tolerability of single ascending doses in overweight and obese adults.
- NBIP-'1968 is designed for once-weekly subcutaneous administration with balanced glucagon activity.
- Neurocrine's obesity portfolio also includes NBIP-'2118, a Phase 1 corticotropin-releasing factor type 2 receptor agonist.
The big picture
Neurocrine's initiation of this Phase 1 trial underscores the growing focus on multi-receptor agonist therapies for obesity, a market with significant unmet needs. The company is positioning itself as a key player by exploring complementary mechanisms to improve weight loss outcomes while addressing challenges like gastrointestinal tolerability and muscle preservation.
What we're watching
- Clinical Progress
- Whether NBIP-'1968 demonstrates sufficient safety and tolerability to advance to later-stage trials.
- Pipeline Strategy
- How Neurocrine's combination approach with NBIP-'2118 may differentiate its obesity portfolio.
- Market Positioning
- The pace at which Neurocrine can establish itself in the competitive obesity treatment landscape.
Related topics